1
|
van Bremen K, Parczewski M, Monin M, Leszczyszyn-Pynka M, Schlabe S, Lenkiewicz F, Karasińska-Cieślak M, Wasmuth JC, Witak-Jędra M, Breitschwerdt S, Rockstroh JK, Zhyvytsia D, Boesecke C, Chober D, Aksak-Wąs B. HIV Care in Ukrainian Migrants in Two European Countries: All the Same? Pathogens 2024; 13:621. [PMID: 39204222 PMCID: PMC11356781 DOI: 10.3390/pathogens13080621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2024] [Revised: 07/16/2024] [Accepted: 07/18/2024] [Indexed: 09/03/2024] Open
Abstract
Introduction: War in Ukraine prompted an enormous refugee influx into Europe, including approximately 4200 people with HIV. The unique healthcare features of Ukrainian refugees living with HIV were compared between two infectious disease departments in Bonn, Germany, and Szczecin, Poland. Methods: This is a retrospective study on 161 people living with HIV (PLWH) refugees from Ukraine seeking care in Bonn (n = 30) and Szczecin (n = 131) between April 2022 and May 2023. Demographic, virologic, immunologic, and coinfection data were analyzed. Results: The majority of the studied individuals were female: 64% (n = 84) in Szczecin and 60% (n = 18) in Bonn. The main HIV transmission mode was heterosexual sex in 73.5% (n = 114). All were on combined antiretroviral therapy (cART) on arrival, primarily on the TLD regimen (TDF/3TC/DTG) (68.4%, n = 106). In Germany, cART was most frequently switched to BIC/TAF/FTC in 83.4% (n = 25); in Poland, the most common combination was TDF/FTC + DTG (58%, n = 76). A prevalence of replicating hepatitis C was in 11.7% (n = 15), and that for chronic hepatitis B (HBV) was in 4.7% (n = 4). History of past tuberculosis was reported in 16.9% (n = 14, Poland, and n = 7, Germany). Follow-up after 6 months showed immunological reconstitution with a mean increase of CD4+ of 10 (IQR: -69.5-120.5) cells/µL in Poland and 51.5 (IQR: -22.5-135.5) cells/µL in Germany; p = 0.04. Virologic suppression (<40 HIV-RNA/mL) was high in care entry (n = 62; 98%) for Poland, and n = 26 (92.6%) for Germany, and suppression was achieved in the majority of patients in the 6-month control (89.7% in Poland vs. 95.7% in Germany). Conclusions: Health challenges posed by war migration extend beyond HIV to coinfections as HBV, HCV, and tuberculosis give an indication for a broader search for coinfections, often less common in the new country.
Collapse
Affiliation(s)
- Kathrin van Bremen
- Bonn University Hospital, 53127 Bonn, Germany; (K.v.B.); (M.M.); (S.S.); (J.-C.W.); (S.B.); (J.K.R.); (C.B.)
- German Centre for Infection Research (DZIF), 53127 Bonn, Germany
| | - Miłosz Parczewski
- Department of Infectious, Tropical Diseases and Acquired Immunodeficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; (M.P.); (M.K.-C.); (D.C.)
- Department of Infectious, Tropical Diseases and Immune Deficiency, Provincial Hospital, 71-455 Szczecin, Poland; (M.L.-P.); (M.W.-J.); (D.Z.)
| | - Malte Monin
- Bonn University Hospital, 53127 Bonn, Germany; (K.v.B.); (M.M.); (S.S.); (J.-C.W.); (S.B.); (J.K.R.); (C.B.)
- German Centre for Infection Research (DZIF), 53127 Bonn, Germany
| | - Magdalena Leszczyszyn-Pynka
- Department of Infectious, Tropical Diseases and Immune Deficiency, Provincial Hospital, 71-455 Szczecin, Poland; (M.L.-P.); (M.W.-J.); (D.Z.)
| | - Stefan Schlabe
- Bonn University Hospital, 53127 Bonn, Germany; (K.v.B.); (M.M.); (S.S.); (J.-C.W.); (S.B.); (J.K.R.); (C.B.)
- German Centre for Infection Research (DZIF), 53127 Bonn, Germany
| | - Franciszek Lenkiewicz
- Department of Infectious, Tropical Diseases and Acquired Immunodeficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; (M.P.); (M.K.-C.); (D.C.)
| | - Malwina Karasińska-Cieślak
- Department of Infectious, Tropical Diseases and Acquired Immunodeficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; (M.P.); (M.K.-C.); (D.C.)
- Department of Infectious, Tropical Diseases and Immune Deficiency, Provincial Hospital, 71-455 Szczecin, Poland; (M.L.-P.); (M.W.-J.); (D.Z.)
| | - Jan-Christian Wasmuth
- Bonn University Hospital, 53127 Bonn, Germany; (K.v.B.); (M.M.); (S.S.); (J.-C.W.); (S.B.); (J.K.R.); (C.B.)
- German Centre for Infection Research (DZIF), 53127 Bonn, Germany
| | - Magdalena Witak-Jędra
- Department of Infectious, Tropical Diseases and Immune Deficiency, Provincial Hospital, 71-455 Szczecin, Poland; (M.L.-P.); (M.W.-J.); (D.Z.)
| | - Sven Breitschwerdt
- Bonn University Hospital, 53127 Bonn, Germany; (K.v.B.); (M.M.); (S.S.); (J.-C.W.); (S.B.); (J.K.R.); (C.B.)
- German Centre for Infection Research (DZIF), 53127 Bonn, Germany
| | - Jürgen K. Rockstroh
- Bonn University Hospital, 53127 Bonn, Germany; (K.v.B.); (M.M.); (S.S.); (J.-C.W.); (S.B.); (J.K.R.); (C.B.)
- German Centre for Infection Research (DZIF), 53127 Bonn, Germany
| | - Dmytro Zhyvytsia
- Department of Infectious, Tropical Diseases and Immune Deficiency, Provincial Hospital, 71-455 Szczecin, Poland; (M.L.-P.); (M.W.-J.); (D.Z.)
| | - Christoph Boesecke
- Bonn University Hospital, 53127 Bonn, Germany; (K.v.B.); (M.M.); (S.S.); (J.-C.W.); (S.B.); (J.K.R.); (C.B.)
- German Centre for Infection Research (DZIF), 53127 Bonn, Germany
| | - Daniel Chober
- Department of Infectious, Tropical Diseases and Acquired Immunodeficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; (M.P.); (M.K.-C.); (D.C.)
- Department of Infectious, Tropical Diseases and Immune Deficiency, Provincial Hospital, 71-455 Szczecin, Poland; (M.L.-P.); (M.W.-J.); (D.Z.)
| | - Bogusz Aksak-Wąs
- Bonn University Hospital, 53127 Bonn, Germany; (K.v.B.); (M.M.); (S.S.); (J.-C.W.); (S.B.); (J.K.R.); (C.B.)
- Department of Infectious, Tropical Diseases and Acquired Immunodeficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; (M.P.); (M.K.-C.); (D.C.)
- Department of Infectious, Tropical Diseases and Immune Deficiency, Provincial Hospital, 71-455 Szczecin, Poland; (M.L.-P.); (M.W.-J.); (D.Z.)
| |
Collapse
|
2
|
Aksak-Wąs BJ, Kowalska JD, Ząbek P, Serwin K, Rafalska-Kosior M, Gołąb J, Chober D, Skonieczna-Żydecka K, Hackiewicz M, Parczewski M. Immune restoration affects 10-year survival in people living with HIV/AIDS. HIV Med 2023; 24:325-334. [PMID: 36054430 DOI: 10.1111/hiv.13391] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 08/08/2022] [Indexed: 11/29/2022]
Abstract
INTRODUCTION In recent years, a reduction in the life expectancy gap between people living with HIV (PLWH) and the general population has been observed, irrespective of CD4 lymphocyte count, due to widespread access to antiretroviral treatment. The increase in the life expectancy of PLWH has increased awareness of both the ageing process and gender discrepancies in immune restoration and survival. MATERIALS AND METHODS Longitudinal data were collected for 2240 patients followed up at the Hospital for Infectious Diseases in Warsaw, Poland (n = 1482), and the Department of Acquired Immunodeficiency, Pomeranian Medical University, Szczecin, Poland (n = 758). Immune restoration was measured from the time of starting combination antiretroviral therapy until achieving 500 CD4 lymphocytes/μL, 800 CD4 lymphocytes/μL, and CD4/CD8 lymphocyte ratios of > 0.8 and > 1.0. Full recovery was achieved when the patient was restored to both 800 CD4 lymphocytes/μL and a CD4/CD8 lymphocyte ratio > 1.0. RESULTS For all endpoints, immune restoration had a protective effect by reducing mortality. Patients who achieved immune restoration had a greater chance of reduced mortality than those who did not achieve immune restoration: for CD4 count > 500 cells/μL, HR = 5.4 (interquartile range: 3.09-9.41), p < 0.001; for CD4 > 800 cells/μL, HR = 5.37 (2.52-11.43), p < 0.001; for CD4/CD8 ratio > 0.8, HR = 3.16 (1.81-5.51), p < 0.001; for CD4/CD8 ratio > 1.0, HR = 2.67 (1.49-5.24), p = 0.001, and for full immune recovery, HR = 3.62 (1.63-8.04), p = 0.002. CONCLUSIONS Immune restoration remains a powerful factor in improving the survival of PLWH, regardless of the speed of recovery.
Collapse
Affiliation(s)
- Bogusz Jan Aksak-Wąs
- Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland
| | - Justyna D Kowalska
- Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.,Hospital for Infectious Diseases in Warsaw, Warsaw, Poland
| | - Piotr Ząbek
- Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland
| | - Karol Serwin
- Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland
| | - Milena Rafalska-Kosior
- Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland
| | - Joanna Gołąb
- Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland
| | - Daniel Chober
- Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland
| | | | - Małgorzata Hackiewicz
- Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.,Hospital for Infectious Diseases in Warsaw, Warsaw, Poland
| | - Miłosz Parczewski
- Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland
| |
Collapse
|